Kymera Therapeutics, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Kymera Therapeutics, Inc. (KYMR), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are KYMR insiders buying or selling?
In the last 12 months, Kymera Therapeutics, Inc. insiders reported 1 open-market purchase ($172.5M) and 46 sales ($471.0M) — net selling of $298.5M. Since February 2021, Trabud has recorded 130 Form 4 filings for KYMR: 13 buys ($286.1M) and 117 sells ($689.1M).
Source: SEC EDGAR Form 4
Key Statistics (February 2021 – Oct 1, 2026)
Total Form 4 filings
130
SEC EDGAR
Insider filers
18
Insider buys (13)
$286.1M
Insider sells (117)
$689.1M
Insider sentiment
Net sellingNet insider flow of $403.0M in net selling since February 2021, and $298.5M in net selling over the last 12 months.
Recent KYMR insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | Nello Mainolfi | Chief Executive Officer | Sale | 30.0K | $113.80 | $3.4M | SEC ↗ |
| Sep 4, 2026 | Brian Adams | Chief Legal Officer | Sale | 6.4K | $116.83 | $744.3K | SEC ↗ |
| Jul 8, 2026 | Nello Mainolfi | Chief Executive Officer | Sale | 50.0K | $119.00 | $6.0M | SEC ↗ |
| Jul 2, 2026 | Bruce N. Jacobs | Chief Financial Officer | Sale | 77.1K | $114.96 | $8.9M | SEC ↗ |
| Jul 2, 2026 | Noah Goodman | Chief Business Officer | Sale | 3.4K | $114.29 | $387.3K | SEC ↗ |
| Jul 2, 2026 | Nello Mainolfi | Chief Executive Officer | Sale | 80.0K | $115.29 | $9.2M | SEC ↗ |
| Jun 30, 2026 | Bruce Booth | Director | Sale | 31.3K | $109.48 | $3.4M | SEC ↗ |
| Jun 30, 2026 | Bruce Booth | Director | Sale | 513.2K | $110.01 | $56.5M | SEC ↗ |
| Jun 26, 2026 | Mark N Lampert | Director | Sale | 1.6M | $106.50 | $173.7M | SEC ↗ |
| Jun 26, 2026 | Bruce Booth | Director | Sale | 285.7K | $121.86 | $34.8M | SEC ↗ |
| Jun 26, 2026 | Bruce Booth | Director | Sale | 398.8K | $110.31 | $44.0M | SEC ↗ |
| Jun 25, 2026 | Noah Goodman | Chief Business Officer | Sale | 5.0K | $114.00 | $570.0K | SEC ↗ |
| Jun 23, 2026 | Bruce Booth | Director | Sale | 31.8K | $103.75 | $3.3M | SEC ↗ |
| Jun 23, 2026 | Bruce Booth | Director | Sale | 478.2K | $94.72 | $45.3M | SEC ↗ |
| Jun 22, 2026 | Noah Goodman | Chief Business Officer | Sale | 2.5K | $99.00 | $247.5K | SEC ↗ |
| May 27, 2026 | Jeremy G Chadwick | Chief Operating Officer | Sale | 17.2K | $79.92 | $1.4M | SEC ↗ |
| May 11, 2026 | Elena Ridloff | Director | Sale | 3.0K | $87.00 | $261.0K | SEC ↗ |
| Apr 29, 2026 | Nello Mainolfi | Chief Executive Officer | Sale | 30.0K | $81.18 | $2.4M | SEC ↗ |
| Apr 24, 2026 | Bruce Booth | Director | Sale | 6.0K | $89.96 | $539.8K | SEC ↗ |
| Apr 24, 2026 | Jeremy G Chadwick | Chief Operating Officer | Sale | 300 | $90.00 | $27.0K | SEC ↗ |
| Apr 16, 2026 | Noah Goodman | Chief Business Officer | Sale | 1.3K | $90.00 | $121.2K | SEC ↗ |
| Apr 16, 2026 | Jeremy G Chadwick | Chief Operating Officer | Sale | 6.6K | $90.00 | $589.6K | SEC ↗ |
| Apr 16, 2026 | Bruce Booth | Director | Sale | 9.5K | $90.01 | $854.5K | SEC ↗ |
| Apr 10, 2026 | Noah Goodman | Chief Business Officer | Sale | 10.3K | $87.47 | $897.8K | SEC ↗ |
| Apr 1, 2026 | Jeremy G Chadwick | Chief Operating Officer | Sale | 22.2K | $85.43 | $1.9M | SEC ↗ |
Showing the 25 most recent of 130 Form 4 filings for Kymera Therapeutics, Inc..
Most active KYMR insiders
- Nello Mainolfi22 filings
- Bruce Booth20 filings
- Jared Gollob14 filings
- Bruce N. Jacobs13 filings
- Mark N Lampert11 filings
Ask anything about KYMR insider activity
Use Trabud's AI agent to query Kymera Therapeutics, Inc.'s Form 4 history in plain English — "Show me KYMR CEO purchases this year" or compare it against any other ticker.
Open the AI agentKYMR insider trading FAQ
Are Kymera Therapeutics, Inc. insiders buying or selling?
In the last 12 months, Kymera Therapeutics, Inc. insiders reported 1 open-market purchase ($172.5M) and 46 sales ($471.0M) — net selling of $298.5M. Since February 2021, Trabud has recorded 130 Form 4 filings for KYMR: 13 buys ($286.1M) and 117 sells ($689.1M). Over the full record that is net selling of $403.0M.
How many insiders trade KYMR stock?
18 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Kymera Therapeutics, Inc.. The most recent filing was accepted on Oct 1, 2026.
Where does Trabud get KYMR insider trading data?
All KYMR insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.